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Abstract 
Somatostatin-14 (SS) si gnificantly increased inositol-l,4,5-trisphosphate (IP3) accumulation i rat hypothalamic, striatal, frontopa- 
rietal cortical and hippocarapal s ices. However, this stimulation of IP 3 accumulation by SS was highest in the frontoparietal cortex and 
hippocampus. The effect was already significant with 0.01/~M in the frontoparietal cortex (P < 0.05) and hippocampus (P < 0.05) and 
the maximal accumulation was evident with 0.1/tM SS, in all areas studied. A concentration of 1/~M SS, lacked this effect in hypo- 
thalamus and striatum. SS rapidly increased IP 3 accumulation i all brain areas tudied. This effect was maximal at 15 s of incubation 
and decreased subsequently. At 60 s incubation, levels were still elevated in frontoparietal cortex and hippocampus but had returned to 
basal values in hypothalamus and striatum. Somatostatin-28 (SS-28) and the SS analogues, D-Trp8-D-Cys 14 and SMS 201-995, also 
significantly stimulated IP~ accumulation although the effect of SMS 201-995 was greater than that of SS in the striatum in comparison 
with controls (P < 0.001 and P < 0.01, respectively). These results uggest that SS action at the hypothalamus, striatum, frontoparietal 
cortex and hippocampus is mediated at least in part by the accumulation of IP 3, which may initiate intracellular processes responsible 
for some biological SS effects. 
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The tetradecapeptide somatostatin-14 (SS), is widely 
distributed through the central nervous system (CNS) 
[22]. Its highest concentration is found in the hypothala- 
mus [22]. SS acts in the CNS as a neurotransmitter or 
neuromodulator, in both an excitatory and inhibitory 
manner [7]. The action:~ of SS are mediated through its 
specific receptors (SSTRs) [6,7,19,26]. Up to now, five 
subtypes of SSTRs have been cloned (SSTR1 to SSTR5) 
[9,10]. SSTRs have been reported to be coupled to several 
intracellular effector systems, including adenylate cyclase 
[23] and ion channels [2,0,31 ]. Recent studies uggest that 
inositol-l,4,5-trisphosphate (IP3) is also involved in the 
mechanism of action of SS [1,12,13,15,16,18,25]. The 
SSTRs in hypothalamus and striatum, two specific areas 
for SS action [7,8,28], are coupled to phospholipase C 
* Corresponding author, Fag:: +34 1 8854585. 
(PLC) [1]. The facts that SS stimulates phosphoinositide 
(PI) hydrolysis in the hippocampus [12,25] and that the 
hippocampus and striatum are closely associated struc- 
tures [27], suggest that SS can also modify IP 3 accumula- 
tion in this brain area. However, to date the effect of SS 
on accumulation of IP 3 in the hypothalamus and striatum 
is unknown. The present study was undertaken to deter- 
mine the effect of SS on accumulation of IP 3 in rat hypo- 
thalamic and striatal slices. In order to compare with other 
brain areas, the frontoparietal cortex and hippocampus 
were also studied. 
SS and somatostatin-28 (SS-28) were purchased from 
Universal Biologicals Ltd. (Cambridge, UK); SMS 201- 
995 from Sandoz (Basel, Switzerland); IP 3 and inositol- 
1,2,3,4,5,6-hexaphosphate (IP6) from Calbiochem (San 
Diego, CA, USA); [3H]IP3 from Du Pont (Boston, MA, 
USA); and DL-dithiothreitol (DTT) from Sigma (St Louis, 
MO, USA). 
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Fig. 1. Concentration-dependent effect of SS-14 on the accumulation of
IP 3 in frontoparietal cortex, hippocampal, hypothalamic and striatal 
slices. Brain slices were incubated for 15 s at 37°C with the different 
concentrations of SS-14. Values are expressed as the mean +_ SEM of 
five separate experiments. Statistical comparison versus control: 
*P < 0.05, **P < 0.01 and ***P < 0.001. 
Cross-chopped brain slices (350 x 350/tm) were pre- 
pared from male Wistar rats (230-250 g) and preincu- 
bated for 45 min at 37°C in Krebs bicarbonate buffer 
(118 mM NaC1, 4.7 mM KC1, 1.3 mM CaCI2, 1.2 mM 
KH2PO4, 1.2 mM MgSO4, 25 mM NaHCO3, 11.7 mM 
glucose, pH 7.4, saturated with O2/CO2 (95:5)) with 
buffer replacement and gassification every 15 min [4]. 
Slices were allowed to sediment and 50/tl of packed 
slices were added to 220/~1 Krebs buffer; these samples 
were gassed regularly, capped and incubated. All addi- 
tions of test substances were made in a volume of 30ktl. 
Incubations were terminated by addition of 300ktl 15% 
trichloroacetic acid (TCA). Acidified samples were left 
on ice for 15 min and centrifuged for 5 min at 2000 x g. 
The supernatants (500kd) were left for 15 min at room 
temperature and then TCA was removed by five succes- 
sive washings with 2 vols. of water-saturated diethyl ether 
and the addition of 125 ktl 30 mM EDTA and 30/~1 6 mM 
NaHCO3. The protein concentration was determined in 
the tissue pellets according to the method of Lowry et al. 
[14]. 
The specific binding of [3H]IP3;to a particulate prepa- 
ration of bovine adrenal cortex was' used as a radiorecep- 
tor assay to determine the concentration of IP 3 in these 
slices by the method described by Challis et al. [4]. Ali- 
quots of the binding protein obtained previously [4] were 
dissolved in 0.05% sodium azide, 5 mM EDTA, 5 mM 
EGTA, 50 mM TAPS (pH 8.6), at a protein concentration 
of 1.5 mg/ml. Then 3.5 × 10 -2 ktCi of [3H]IP3 was added 
per ml of solution to prepare the receptor-tracer solution. 
Assays were performed in a final volume of 500/~1. Re- 
ceptor-tracer solution (400ktl) was added to 100ktl of 
unknown samples or 100/~1 of standard samples contain- 
ing IP3 (0.6-24 pmol in 1 mM EDTA, 1 mM EGTA, pH 
7.5) or IP 6 (1% w/v in 20 mM EDTA, 20 mM EGTA, 
0.05% sodium azide, pH 7.5) to define non-specific 
binding. All tubes were incubated for 1 h at 4°C. Separa- 
tion of bound and free IP 3 was achieved by centrifugation 
at 12 000 x g for 10 min. After aspiration of the super- 
natant, 50/~1 of 0.15 M NaOH was added to each tube 
and the pellet dissolved by shaking. The radioactivity was 
determined by liquid scintillation spectrometry. The IP 3 
content was determined by comparing the extent of the 
inhibition of [3H]IP3 binding with a calibration curve ob- 
tained with known amounts of IP 3. Non-specific binding 
was about 13% of the total binding. 
Statistical comparisons of all the data were analyzed 
by ANOVA and the Newman-Keuls t-test. Means be- 
tween groups were considered significantly different 
when the P value was less than 0.05. Each individual ex- 
periment was performed in duplicate. 
SS significantly increased IP 3 accumulation i all brain 
areas investigated and this increase was highest in the 
frontoparietal cortex and hippocampus (Fig. 1). The effect 
was already significant with 0.01/tM in the frontoparietal 
cortex (P < 0.05) and hippocampus (P < 0.05) and the 
maximal accumulation was evident at 0.1 ktM SS, in all 
areas studied (2.1, 1.9, 1.8 and 1.7-fold increase over ba- 
sal values in frontoparietal cortex, hippocampal, hypotha- 
lamic and striatal slices, respectively). A concentration of
1 ktM SS lacked this effect in striatum and hypothalamus. 
Since there are five SS receptor subtypes, SSTR1-5, in 
the CNS [10], and their number, affinity for SS [10] and 
ability to activate PLC [1] all vary, an explanation for this 
result could be that IP 3 accumulation occurs with higher 
affinity receptors. Occupation of lower affinity receptors 
by SS might reduce accumulated IP3. 
SS rapidly increased IP 3 accumulation i all brain ar- 
eas studied (Fig. 2). This effect was maximal at 15 s of 
incubation and decreased subsequently. After 60 s the 
levels in frontoparietal cortex and hippocampus were still 
elevated whereas those in hypothalamus and striatum 
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Fig. 2. Time-course ffect of 10 -7 M of SS-14-induced IP3 accumula- 
tion in frontoparietal cortex, hippocampal, hypothalamic and striatal 
slices. Values are expressed as the mean __. SEM of five separate x- 
periments. Statistical comparison versus control: *P < 0.05, **P < 0.01 
and ***P < 0.001. B, basal. 
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Fig. 3. Effect of various SS ~tnalogues on IP 3 accumulation i fronto- 
parietal cortex, hippocampal, hypothalamic and striatal slices. Brain 
slices were incubated for 15 s at 37°C with 10 -7 M of the different SS 
peptides. Values are expressed as the mean _+ SEM of five separate 
experiments. Empty bars co~rrespond to the basal values. Statistical 
comparison versus control: *P < 0.05, **P < 0.01 and ***P < 0.001. 
The effects of SS-28 and two SS analogues, D-TrpS-D -
Cys ~4 and SMS 201-995, on IP 3 accumulation were also 
studied. All peptides ignificantly stimulated IP 3 accumu- 
lation although the effect of SMS 201-995 was higher 
than that of SS in the striatum in comparison with con- 
trois (P < 0.001 and P < 0.01 respectively) (Fig. 3). In the 
hypothalamus the effect of SMS 201-995 also seems to 
be greater than SS but this difference is not statistically 
significant (Fig. 3). 
A similar effect of SS on IP3 accumulation has already 
been observed in cerebral cortex [12], hippocampus 
[12,15], pituitary gland [12], bovine adrenal gland [18], 
SSTRl-expressing Chinese hamster ovary (CHO) cells 
[11] and COS-7 cells transfected with human SS recep- 
tors (hSSTR) [29]. The regional pattern of SS response 
may be accounted for by the regional distribution of 
SSTRs [6,26] or may be due to a regional difference in 
the efficiency of the coupling mechanism, perhaps via 
nucleotide-regulated protein [5] between the SSTRs sub- 
types and PLC. 
The effect of SS on IP 3 accumulation seems to be a di- 
rect consequence of SSTR occupancy. Recently, it has 
been reported that cloned hSSTR subtypes 1-5 activate 
PLC and mobilize Ca 2+ in transfected COS-7 cells [1]. 
Activation of PLC by SS is in the order hSSTR5 > 
hSSTR2 > hSSTR3 > hSSTR4 > hSSTR1 [1]. The hypo- 
thalamus hows a very high level of SSTR5 expression 
and moderate levels of other subtypes of SSTR coupled to 
PLC [10]. The fact that SS does not increase further IP 3 
accumulation in the hypothalamus could be due to the 
high endogenous SS content [22]. Expression of these 
SSTR subtypes in striatt,m and other brain areas has been 
reported [10]. However, since cyclic AMP (cAMP) has 
been shown to inhibit PI breakdown in a number of cell 
systems [20] and SS decreases cAMP levels [23], it is 
possible that the IP3 accumulation i duced by SS could 
also occur at the cAMP level. 
The SS concentration eliciting the maximal IP 3 accu- 
mulation was about two orders of magnitude higher than 
the corresponding binding affinities obtained in previous 
studies [6,19,26]. This discrepancy can be explained by 
the different experimental conditions used in each type of 
experiment. Our previous binding studies were obtained 
at equilibrium after an incubation of 60 min at 30"C [19]. 
In contrast, IP 3 accumulation is a transient process that 
must be measured 15 s after exposing brain slices to SS. 
Therefore, this very short time may not be sufficient o 
reach binding equilibrium. The fast and transitory charac- 
ter of IP 3 formation is compatible with a function of this 
molecule as a second messenger. 
Whether or not the SS-evoked IP 3 accumulation i the 
slices is derived from neuronal ceils is unknown. In this 
regard, SS is known to potentiate de-al-adrenergic a ti- 
vation of PLC in striatal astrocytes [16]. Therefore, the 
possibility that the SS-evoked increase in IP 3 accumula- 
tion in the studied brain slices could be derived from glial 
cells cannot be excluded. SS directly activates erotoner- 
gic and dopaminergic nerve terminals to release serotonin 
[28] and dopamine [8], respectively, and this is additional 
support for the notion that SS acts, at least in part, on IP 3 
signaling in the hypothalamic, striatal, hippocampal and 
cortical neurons. 
The robust IP 3 response produced by SMS 201-995 
may be due to the activation of SSTR subtypes that have 
very high affinity (SSTR2, SSTR5) or some affinity 
(SSTR3) for this SS analogue [10] and that powerfully 
activate the PLC-Ca 2÷ system [ 1]. 
The accumulation of IP 3, which is known to release 
calcium from internal stores [2] may provide a mecha- 
nism for the SSTRs-mediated cellular effects of SS. A 
few studies have reported that SS activates PLC followed 
by Ca 2+ mobilization in native SS receptor-expressing 
cells such as striatal astrocytes [16] and NG 108-15 neu- 
roblastoma x glioma hybrid cells (NG 108-15 cells) 
[21 ]. A requirement for Ca2+-dependent phospholipase A2 
activation has also been postulated in SS actions in hip- 
pocampal cells [24]. SS facilitates neurotransmitter re- 
lease [8,28], long-term potentiation [17] and neurite 
growth [3]. All these responses may be secondary to re- 
ceptor-mediated PI hydrolysis and subsequent mobiliza- 
tion of intracellular Ca 2+ [2]. 
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